SWOG S1803 (Multiple Myeloma) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to see if adding the experimental drug daratumumab/rHuPH20 to the standard treatment after stem cell transplants can help multiple myeloma patients live longer.

What is the Condition Being Studied?

Multiple myeloma patients who have received a stem cell transplant

Who Can Participate in the Study?

Adults with multiple myeloma who have had a stem cell transplant.

Age Group

What is Involved?

If you choose to join this study, you will get a random assignment (like flipping a coin) to 1 of 2 groups:

  • One group will take the standard maintenance drug, lenalidomide, and the study drug daratumumab/rHuPH20
  • The other group will take lenalidomide alone
  • Study Details

    Full Title
    SWOG S1803: Phase III Study of Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
    Principal Investigator
    Cellular Therapy Specialist
    Protocol Number
    IRB: PRO00104040
    NCT: NCT04071457
    Phase III
    Enrollment Status
    Open for Enrollment